Skip to main content

Orthocell heartened by US progression

09/05/2025 - 14:28

Bookmark

Save articles for future reference.

Orthocell boss Paul Anderson said the Murdoch-based biotech medical company is “well ahead” of its original targets in relation to US sales of its nerve repair product, Remplir.

To read our articles you will need to either login or subscribe.